Cortés EOD, Raya GLP, Alvarado VLB, Garza HEI, Vázquez CJJ

Language: Spanish
References: 11
Page: 453-457
PDF size: 204.29 Kb.

ABSTRACT

Introduction: Transient Neonatal Myasthenia gravis (TNMG) is an infrequent pathology reported in a small number of babies born from mothers with a diagnosis of Myasthenia gravis. Is produced by the transplacental passage of maternal antibodies, and has a broad spectrum of clinical manifestations, most of them of neuromuscular origin. Diagnosis is clinical and is supported by the presence of antibodies in the neonatal circulation.
Clinical case: We present the case of a female newborn whose mother had a 3-year history of Myasthenia gravis, which presented with hypotonia, a weak cry, and weak suction at the first hour of life, she developed severe respiratory weakness so a cholinesterase inhibitor was initiated, with immediate clinical improvement. Nevertheless, the general state deteriorates and requires to be admitted to the Neonatal Intensive Care Unit. Neonatal antibodies were taken on the 19th day of life, resulting in a negative. It is discharged with neostigmine treatment orally, one month after her admission.
Conclusions: TNMG manifestations typically occur in the first hours of life, and symptom duration is usually lower than four weeks, the period in which maternal antibodies usually last. Treatment is based on acetylcholinesterase inhibitors. TNMG Diagnosis is clinical and should be done in susceptible patients.

REFERENCES

1. Gilhus NE, Hong Y. Maternal myasthenia gravis representsa risk for the child through autoantibody transfer, immunosuppressivetherapy and genetic influence. Eur J Neurol. 2018; 25(12), 1402–1409.

2. Gilhus NE. Myasthenia Gravis Can Have Consequencesfor Pregnancy and the Developing Child. Front Neurol.2020; 11:1-6.

3. Gilhus NE. Treatment considerations in myasthenia gravisfor the pregnant patient. Expert Rev Neurother. 2023; 23(2), 169-177.

4. Townsel C, Keller R, Johnson K, Hussain N, Campbell W.Seronegative Maternal Ocular Myasthenia Gravis andDelayed Transient Neonatal Myasthenia Gravis. AJP Rep.2016; 06(01), e133–e136.

5. Djelmis J, Sostarko M, Mayer D, Ivanisevic M. Myastheniagravis in pregnancy: report on 69 cases. Eur J Obstet GynecolReprod Biol. 2002; 104, 21–25.

6. Iijima S. Clinical and pathophysiologic relevance of autoantibodiesin neonatal myasthenia gravis. Pediatr Neonatol.2021; 62 (6) 581–590.

7. Lee JY, Min JH, Han SH, Han J. Transient neonatal myastheniagravis due to a mother with ocular onset of anti-musclespecific kinase myasthenia gravis. Neuromuscul Disord.2017; 27(7), 655–657.

8. Santiago-Gonçalves C, Nunes-Marques MI, Antunes S,Serrano A. (2021). Transient Neonatal Myasthenia Gravis:A Case Report. Cureus. 13 (12) 1-5.

9. Papazian O. Transient Neonatal Myasthenia Gravis. J ChildNeurol. 1992; 7, 135–141.

10. Kochhar PK, Schumacher RE, Sarkar S. Transient neonatalmyasthenia gravis: refining risk estimate for infants bornto women with myasthenia gravis. J Perinatol. 2021; 41(9),2279–2283.

11. Vernet-Der B, Lacokova M, Eymard B, Morel E, Faltin M,Zajac J, et al (1994). Association of neonatal myastheniagravis with antibodies against the fetal acetylcholine receptor.J Clin Invest. 1994; 94(2), 555–559.